To access this element change to forms mode OFF
Grant Award View - GA31903
Understanding high-level resistance to antimalarial PfATP4 inhibitors
GA ID:
GA31903
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
10-Jan-2019
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2020
Value (AUD):
$325,997.70
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Understanding high-level resistance to antimalarial PfATP4 inhibitors
Purpose:
Recent years have seen new, urgently-needed malaria medicines enter the clinical development pipeline. One new medicine that has performed very well in clinical studies is cipargamin. Unfortunately, we have shown that malaria parasites grown in the laboratory are capable of acquiring a high level of resistance to this medicine. We seek to understand the cause and features of this high level resistance in order to assess the magnitude of the threat it poses and devise risk mitigation strategies.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1159648
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
Australian National University
Recipient ABN:
52 234 063 906
Grant Recipient Location
Suburb:
Canberra City
Town/City:
Canberra City
Postcode:
2601
State/Territory:
ACT
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
ACT
Postcode:
Country:
AUSTRALIA